Non-Fecal Microbiota Transplantation Strategies Show Promise for Recurrent *Clostridioides difficile* Infection

Clostridioides difficile infection (CDI) is a leading healthcare-associated illness characterized by high recurrence rates and significant clinical burden. Recurrent CDI (rCDI) often stems from severe microbiota disruption, frequently exacerbated by antibiotic therapies that further deplete beneficial gut bacteria. Current standard treatments, such as fidaxomicin and vancomycin taper regimens, are effective but do not fully address the underlying dysbiosis, leading to persistent vulnerability to recurrence. The re-establishment of a normal bile acid composition in the colon is critical, as primary bile acids are potent germinators of C. difficile, and their imbalance contributes to rCDI pathogenesis.

This review systematically examined non-fecal microbiota transplantation (FMT) strategies for recurrent Clostridioides difficile infection (rCDI). The authors synthesized current evidence on a range of emerging therapies, including live biotherapeutic products (LBPs), non-toxigenic Clostridioides difficile strains, and various microbiome-protective agents. The scope also encompassed dietary interventions designed to enhance microbial diversity and support gut recovery. The review aimed to identify and characterize these novel approaches that shift the paradigm towards microbiome-centered management, moving beyond traditional antibiotic-only strategies.

The review highlighted several promising non-FMT approaches for recurrent Clostridioides difficile infection (rCDI), emphasizing a paradigm shift towards microbiome-centered management. Live biotherapeutic products (LBPs) and non-toxigenic Clostridioides difficile strains were identified as key emerging therapies, aiming to restore gut microbiota diversity and function. Microbiome-protective agents, which help preserve beneficial bacteria during antibiotic treatment, also showed significant potential by mitigating antibiotic-induced dysbiosis. Dietary interventions that enhance microbial diversity were noted for their supportive role in promoting gut recovery and resilience. > These strategies collectively aim to re-establish a normal bile acid composition in the colon, a crucial factor in preventing C. difficile germination and subsequent recurrence. The findings underscore the importance of targeting the underlying microbiota disruption to achieve sustained resolution of rCDI.